2023, Volume 19

Costs of treatment with cyclin-dependent kinase inhibitors – CDK4/6 in hormone-dependent HER2-negative breast cancer under the B.9 drug programme



Krystyna Futyma1, Patryk Wicher2, Paweł Nurzyński2, Agata Adamczuk-Nurzynska2, Tomasz Lewandowski1, Adam Rzeźnicki3, Grzegorz Kade1, Waldemar Wierzba2, Andrzej Śliwczyński2, Jan Krakowiak3

1Clinical Hospital of the Ministry of the Internal Affairs and Administration with the Warmia-Mazury Oncology Centre in Olsztyn, Olsztyn, Poland
2National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
3Department of Social Medicine, Medical University of Lodz, Lodz, Poland


Author for correspondence: Krystyna Futyma; Clinical Hospital of the Ministry of the Internal Affairs and Administration with the Warmia-Mazury Oncology Centre in Olsztyn, Olsztyn, Poland; email: krystynaf13@wp.pl



Full text

Abstract

Background and Study Aim: Breast cancer stands as the most common malignant tumour among women in Poland and worldwide. It is an extremely heterogeneous disease due to the occurrence of mutations and hormonal dependencies. Presently, generalized breast cancer remains incurable; however, innovative therapies offer opportunities for prolonging survival without disease progression and alleviating symptoms. Notably, the utilization of drugs from the CDK4/6 inhibitor group as a supplement and support in the treatment of hormone-dependent breast cancer with HER2/−/ (HR+ HER2/−/) is a breakthrough in the therapy of this type of cancer. This article aims is knowledge about the costs of treating patients with HR+ HER2/−/ breast cancer with CDK4/6 inhibitors, reimbursed in Poland under the drug program.

Material and Methods: The study utilized relevant cost and revenue data pertaining to the treatment of patients diagnosed with HR+ HER2/−/ breast cancer and treated with CDK4/6 inhibitors under the drug programme B.9 ‘Treatment of Breast Cancer Patients (ICD-10: C-50)’ at the regional oncology centre in north-eastern Poland from 2019 to 2023. Financial categories were presented based on the purchasing power parity of PPP / 1 USD inter.

Results: Between 2019 and 2023, the value of the diagnostic lump sum in the B.9 drug programme underwent four changes (the so-called ‘quality factor’ by the Polish National Health Fund from 2021, increasing the value of the benefit by a multiplier of 1.025, while maintaining the methodology of 1 settlement point = 1 PLN). Subsequent changes in the diagnostic lump sum value stemmed from the increase in the settlement point price: April 2022, 1 point = 1.05 PLN; July 2022, 1 point = 1.37 PLN; July 2023, 1 point = 1.64 PLN.
The value of the benefit for admitting a patient on an outpatient basis increased from 63.66 USD-inter to 101.74 USD-inter in 2023, reflecting a rise of 59.82%. Compared to the average value for 2023 of 93.37 USD-inter, there was an increase in the value of this benefit by 46.67%. The value of drugs administered in 2023 represented about approximately 230% of the therapies delivered in 2020 (the value of stay benefits ranges from 4.30% to 5.20%). In the analysed period, diagnostic costs ranged from 2.30% to 4.10% of the total cost structure.

Conclusions: The utilization of ribociclib and other drugs from the group of CDK4/6 inhibitors as a complement and support to the therapy of hormone-dependent breast cancer with HER2/−/ represents a breakthrough in the treatment of this type of cancer. Ciclibs notably enhance the effectiveness of hormone therapy and improve the prognosis and quality of life of patients with advanced HR+/HER2-negative breast cancer. Moreover, the tablet form of CDK4/6 drugs facilities widespread outpatient treatment while ensuring patient safety. Exclusion of a patient from a drug program due to complications poses a genuine risk of nullifying the financial investments made for the patient’s prior treatment within the program. Underestimation of hospitalization costs similarly poses a tangible risk of financial losses for program implementers, in cases necessitating additional treatment for complications to enable continued therapy.


Key words: abemaciclib, breast cancer, fight against cancer, hormone therapy, palbociclib, ribociclib


Cite this article as:

AMA:

Futyma K, Wicher P, Nurzyński P et al. Costs of treatment with cyclin-dependent kinase inhibitors – CDK4/6 in hormone-dependent HER2-negative breast cancer under the B.9 drug programme. ARCH BUDO. 2023;19

APA:

Futyma, K., Wicher, P., Nurzyński, P., Adamczuk-Nurzynska, A., Lewandowski, T., & Rzeźnicki, A. et al. (2023). Costs of treatment with cyclin-dependent kinase inhibitors – CDK4/6 in hormone-dependent HER2-negative breast cancer under the B.9 drug programme. ARCH BUDO, 19

Chicago:

Futyma, Krystyna, Wicher Patryk, Nurzyński Paweł, Adamczuk-Nurzynska Agata, Lewandowski Tomasz, Rzeźnicki Adam, and Kade Grzegorz et al. 2023. "Costs of treatment with cyclin-dependent kinase inhibitors – CDK4/6 in hormone-dependent HER2-negative breast cancer under the B.9 drug programme". ARCH BUDO 19

Harvard:

Futyma, K., Wicher, P., Nurzyński, P., Adamczuk-Nurzynska, A., Lewandowski, T., Rzeźnicki, A., Kade, G., Wierzba, W., Śliwczyński, A., and Krakowiak, J. (2023). Costs of treatment with cyclin-dependent kinase inhibitors – CDK4/6 in hormone-dependent HER2-negative breast cancer under the B.9 drug programme. ARCH BUDO, 19

MLA:

Futyma, Krystyna et al. "Costs of treatment with cyclin-dependent kinase inhibitors – CDK4/6 in hormone-dependent HER2-negative breast cancer under the B.9 drug programme." ARCH BUDO, vol. 19, 2023

Vancouver:

Futyma K, Wicher P, Nurzyński P et al. Costs of treatment with cyclin-dependent kinase inhibitors – CDK4/6 in hormone-dependent HER2-negative breast cancer under the B.9 drug programme. ARCH BUDO 2023; 19